I 118th CONGRESS 1st Session H. R. 1305 IN THE HOUSE OF REPRESENTATIVES March 1, 2023 Mr. Levin (for himself, Mr. Ferguson , Mr. McGovern , and Mr. Amodei ) introduced the following bill; which was referred to the Committee on Foreign Affairs A BILL To direct the Secretary of Health and Human Services, in consultation with the Secretary of State, to formulate a strategy for the Federal Government to secure support from foreign countries, multilateral organizations, and other appropriate entities to facilitate the development and commercialization of qualified pandemic or epidemic products, and for other purposes.

1. Short title This Act may be cited as the Saving Us from Pandemic Era Resistance by Building a Unified Global Strategy Act of 2023 or the SUPER BUGS Act of 2023 . 2. International strategy for development of qualified pandemic or epidemic products (a) Strategy (1) In general Not later than 18 months after the date of enactment of this Act, the Secretary of Health and Human Services, in consultation with the Secretary of State, shall— (A) formulate a strategy for the Federal Government to secure support from foreign countries, multilateral organizations, and other appropriate entities to facilitate the development and commercialization of qualified pandemic or epidemic products, including such products to address antimicrobial resistant pathogens— (i) with pandemic potential; or (ii) that are priority pathogens; and (B) submit such strategy to the appropriate committees of Congress. (2) Contents The strategy under paragraph (1) shall— (A) provide for the process the Federal Government would use to enter into arrangements with foreign countries, multilateral organizations, and other appropriate entities in certain circumstances; (B) strive to secure equitable contributions among participating countries, organizations, and entities; (C) focus on global priorities but allow participating countries, organizations, and entities to emphasize national or regional issues of importance; (D) seek to ensure such arrangements are harmonized with each other and with other relevant arrangements to prevent duplication of effort and to efficiently distribute funds; (E) provide for collaboration so as to allocate joint or individual responsibility across participating countries, organizations, and entities for the development and commercialization of particular qualified pandemic or epidemic products, where such collaboration is spelled out beforehand in such arrangements; (F) provide for the stewardship of qualified pandemic or epidemic products developed pursuant to the strategy; (G) define criteria so that scarce funds are allocated to advance qualified pandemic or epidemic products that can achieve the greatest positive impact on human health, including unprecedented approaches to preventing, treating, and diagnosing infectious diseases; (H) consider approaches including securing contracts with the private sector, entering into public-private partnerships, implementing alternative payment models, and streamlining regulatory approval processes; and (I) be synchronized with United States pandemic preparedness priorities, such as the U.S. National Action Plan for Combating Antibiotic-Resistant Bacteria (CARB). (b) Arrangements with foreign countries and multilateral organizations The Secretary of Health and Human Services, in consultation with the Secretary of State, shall seek to enter into arrangements with foreign countries, multilateral organizations, and other appropriate entities to implement the strategy under subsection (a). (c) Definition In this section: (1) The term priority pathogens means pathogens identified in the latest Centers for Disease Control and Prevention Antimicrobial Threats Report, the World Health Organization Global Priority Pathogens List, or a successor report or list. (2) The term qualified pandemic or epidemic product has the meaning given to such term in section 319F–3 of the Public Health Service Act ( 42 U.S.C. 247d–6b ).